The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is dedicating an article regarding the study carried out by the laboratory and published in the July issue of the Journal of Nuclear Medicine (see our article).

A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice.

Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.

In the study, researchers and engineers from CARAT (Consortium pour des Applications en Radio Alpha Thérapies coordinated by Stéphanie Durand-Panteix) developed human myeloma cell lines, which were analyzed for cell proliferation after incubation with various concentrations of 212Pb monoclonal antibodies. Mice received subcutaneous grafts of human myeloma cell lines and were injected with 212Pb-anti-CD38, 212Pb-anti-mCD38 (mice-specific) or 212Pb-isotypic control.

Biodistribution, toxicity and dose-range-finding studies were performed, as well as radioimmunotherapy experiments that measured tumor volume and overall survival.